Christian Matthias Wilk

Christian Matthias Wilk

Auto-generated profile, based on publicly available information

Christian Matthias Wilk

Icahn School of Medicine at Mount Sinai

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Immunity
Verified
Journal Article
Closed access
NVNicolas Vabret
Nicolas Vabret
GBGraham Britton
Graham Britton
CGConor Gruber
Conor Gruber
SHSamarth Hegde
Samarth Hegde
JKJoel Kim
Joel Kim
ULUri Laserson
Uri Laserson

25 October 2024 in Science
Verified
Journal Article
Open access
MPMatthew Park
Matthew Park
JBJessica Le Berichel
Jessica Le Berichel
PHPauline Hamon
Pauline Hamon
CWC. Matthias Wilk
C. Matthias Wilk
MBMeriem Belabed
Meriem Belabed
MMMiriam Merad
Miriam Merad
Age is a major risk factor for cancer, but how aging impacts tumor control remains unclear. In this study, we establish that aging of the immune system, regardless of the age of the stroma and tumor, drives lung cancer progression. Hematopoietic aging enhances emergency myelopoiesis, resulting in the local accumulation of myeloid progenitor–like cells in lung tumors. These cells are a major source of interleukin (IL)–1⍺, which drives the enhanced myeloid response. The age-associated decline of DNA methyltransferase 3A enhances IL-1⍺ production, and disrupting IL-1 receptor 1 signaling early during tumor development normalized myelopoiesis and slowed the growth of lung, colonic, and pancreatic tumors. In human tumors, we identified an enrichment for IL-1⍺–expressing monocyte-derived macrophages linked to age, poorer survival, and recurrence, unraveling how aging promotes cancer and offering actionable therapeutic strategies.

25 November 2015 in Leukemia
Verified
Journal Article
Closed access
PDF file
SGS Geyh
S Geyh
MRM Rodríguez-Paredes
M Rodríguez-Paredes
PJP Jäger
P Jäger
CKCyrus Khandanpour
Cyrus Khandanpour
RCR-P Cadeddu
R-P Cadeddu
TST Schroeder
T Schroeder

12 September 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ASAlfonso R. Sánchez-Paulete
Alfonso R. Sánchez-Paulete
JMJaime Mateus-Tique
Jaime Mateus-Tique
GMGurkan Mollaoglu
Gurkan Mollaoglu
SNSebastian R. Nielsen
Sebastian R. Nielsen
AMAdam Marks
Adam Marks
BBBrian D. Brown
Brian D. Brown
Tumor-associated macrophages (TAM) are one of the most abundant cell types in many solid tumors and typically exert protumor effects. This has led to an interest in macrophage-depleting agents for cancer therapy, but approaches developed to date have had limited success in clinical trials. Here, we report the development of a strategy for TAM depletion in mouse solid tumor models using chimeric antigen receptor (CAR) T cells targeting the macrophage marker F4/80 (F4.CAR-T). F4.CAR-T cells effectively killed macrophages in vitro and in vivo without toxicity. When injected into mice bearing orthotopic lung tumors, F4.CAR-T cells infiltrated tumor lesions and delayed tumor growth comparably with PD-1 blockade, and significantly extended mouse survival. Antitumor effects were mediated by F4.CAR-T–produced IFNγ, which promoted upregulation of MHC molecules on cancer cells and tumor-infiltrating myeloid cells. Notably, F4.CAR-T promoted expansion of endogenous CD8 T cells specific for tumor-associated antigen and led to immune editing of highly antigenic tumor cell clones. Antitumor impact was also observed in mouse models of ovarian and pancreatic cancer. These studies provide proof of principle to support CAR T-cell targeting of TAMs as a means to enhance antitumor immunity.

27 September 2012 in Blood
Verified
Journal Article
Closed access
PDF file
IBIngmar Bruns
Ingmar Bruns
RCRon-Patrick Cadeddu
Ron-Patrick Cadeddu
IBInes Brueckmann
Ines Brueckmann
JFJulia Fröbel
Julia Fröbel
SGStefanie Geyh
Stefanie Geyh
RHRainer Haas
Rainer Haas
Multiple myeloma (MM) is a clonal plasma cell disorder frequently accompanied by hematopoietic impairment. We show that hematopoietic stem and progenitor cells (HSPCs), in particular megakaryocyte-erythrocyte progenitors, are diminished in the BM of MM patients. Genomic profiling of HSPC subsets revealed deregulations of signaling cascades, most notably TGFβ signaling, and pathways involved in cytoskeletal organization, migration, adhesion, and cell-cycle regulation in the patients. Functionally, proliferation, colony formation, and long-term self-renewal were impaired as a consequence of activated TGFβ signaling. In accordance, TGFβ levels in the BM extracellular fluid were elevated and mesenchymal stromal cells (MSCs) had a reduced capacity to support long-term hematopoiesis of HSPCs that completely recovered on blockade of TGFβ signaling. Furthermore, we found defective actin assembly and down-regulation of the adhesion receptor CD44 in MM HSPCs functionally reflected by impaired migration and adhesion. Still, transplantation into myeloma-free NOG mice revealed even enhanced engraftment and normal differentiation capacities of MM HSPCs, which underlines that functional impairment of HSPCs depends on MM-related microenvironmental cues and is reversible. Taken together, these data implicate that hematopoietic suppression in MM emerges from the HSPCs as a result of MM-related microenvironmental alterations.

1 May 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
RMRenier Myburgh
Renier Myburgh
JKJonathan D. Kiefer
Jonathan D. Kiefer
NRNorman F. Russkamp
Norman F. Russkamp
CMChiara F Magnani
Chiara F Magnani
NNNicolás Nuñez
Nicolás Nuñez
MMMarkus G. Manz
Markus G. Manz